Type 2 diabetes tablet promotes weight loss

December 6, 2012

(Medical Xpress)—A new drug for type 2 diabetes, involving research at Aston University is being launched as a once-daily tablet for adults with the condition.

Bristol-Myers Squibb and AstraZeneca have launched FORXIGATM (dapagliflozin), a drug which acts independently of insulin to improve and lower body weight.

Professor Clifford Bailey, Professor of Clinical Science at Aston University, has led research into dapagliflozin, a new class of treatments called sodium-glucose cotransporter (SGLT2) inhibitors. These reduce the amount of glucose reabsorbed in the kidney so that excess glucose is passed out of the body via the urine each day.

Professor Bailey's study of patients with type 2 diabetes using dapagliflozin, has provided key information about the drug, which was recently approved for the treatment of this condition. Research showed that it lowers the patient's and promotes weight loss, unlike some diabetes medications that are associated with weight gain.

Dapagliflozin is for use in combination with other glucose lowering treatments, including insulin when these, together with diet and exercise, do not provide adequate blood glucose control in patients. Dapagliflozin can also be used as a monotherapy if diet and exercise do not work in patients for whom the blood glucose lowering agent metformin is not tolerated.

Type 2 Diabetesis a characterized by in the context of and relative . It is initially managed by increasing exercise and dietary modification. If blood glucose levels are not adequately lowered by these measures, medications such as metformin or insulin may be needed. In those on insulin, there is typically the requirement to routinely check blood sugar levels.

Professor Clifford Bailey, author of; "Effect of dapagliflozin in patients with type 2 diabetes", published in The Lancet, said; "dapagliflozin works in a different way to existing treatments. It removes excess glucose from the body along with the associated calories. This process occurs independently of insulin action. So dapagliflozin can be used in conjunction with most commonly used to lower blood glucose, and has the added benefit of weight loss."

Dr Chris Walton, Consultant Diabetologist and Chair of the Association of British Clinical diabetologists, said; "Specialists in diabetes will be keen to work with GPs to assess the place of this new medicine in the treatment of their patients with ."

FORXIGA (dapagliflozin) has been granted marketing authorisation by the European Commission and will be marketed by Bristol-Myers Squibb and AstraZeneca from December 2012.

Explore further: FDA questions safety of experimental diabetes drug

More information: www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60407-2/abstract

Related Stories

Dapagliflozin aids glycemic control in type 2 diabetes

March 20, 2012

(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according to research ...

Recommended for you

A metabolic master switch underlying human obesity

August 19, 2015

Obesity is one of the biggest public health challenges of the 21st century. Affecting more than 500 million people worldwide, obesity costs at least $200 billion each year in the United States alone, and contributes to potentially ...

Scientists probe obesity's ties to breast cancer risk

August 20, 2015

Obesity is a well-known risk factor for breast cancer, but researchers haven't figured out what connects the two. A new study suggests the link may be due to a change in breast tissue structure, which might promote breast ...

Can a new drug brown the fat and trim the obese person?

May 28, 2015

New research has found that a variant of a drug used to treat pulmonary arterial hypertension prompts weight loss in obese mice. Among mice fed a high-fat diet, those who did not get the medication became obese while medicated ...

Changing stem cell structure may help fight obesity

February 17, 2015

The research, conducted at Queen Mary University of London (QMUL), found that a slight regulation in the length of primary cilia, small hair-like projections found on most cells, prevented the production of fat cells from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.